EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Moderna's enterprise value is $61,164 Mil.
Moderna's Revenue for the trailing twelve months (TTM) ended in Jun. 2022 was $22,284 Mil. Therefore, Moderna's EV-to-Revenue for today is 2.74.
The historical rank and industry rank for Moderna's EV-to-Revenue or its related term are showing as below:
MRNA'
s EV-to-Revenue Range Over the Past 10 Years
Min: 2.08 Med: 41.53 Max: 848.62
Current: 2.69
During the past 6 years, the highest EV-to-Revenue of Moderna was 848.62. The lowest was 2.08. And the median was 41.53.
MRNA's EV-to-Revenue is ranked better than 83.73% of 934
companies
in the Biotechnology industry
Industry Median: 11.00
vs MRNA: 2.69
As of today (2022-08-12), Moderna's stock price is $171.81.
Moderna's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2022 was $52.09. Therefore, Moderna's PS Ratio for today is 3.30.
Moderna EV-to-Revenue Historical Data
The historical data trend for Moderna's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Moderna Annual Data
Trend
Dec16
Dec17
Dec18
Dec19
Dec20
Dec21
EV-to-Revenue
-
28.84
116.92
136.10
5.22
Moderna Quarterly Data
Dec16
Dec17
Mar18
Jun18
Sep18
Dec18
Mar19
Jun19
Sep19
Dec19
Mar20
Jun20
Sep20
Dec20
Mar21
Jun21
Sep21
Dec21
Mar22
Jun22
EV-to-Revenue
14.08
13.39
5.22
2.72
2.20
Competitive Comparison
For the Biotechnology subindustry, Moderna's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Moderna EV-to-Revenue Distribution
For the Biotechnology industry and Healthcare sector, Moderna's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where Moderna's EV-to-Revenue falls into.
Moderna's current Enterprise Value is $61,164 Mil.
Moderna's Revenue for the trailing twelve months (TTM) ended in Jun. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $22,284 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Moderna's share price for today is $171.81.
Moderna's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $52.09.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Moderna EV-to-Revenue Related Terms
Thank you for viewing the detailed overview of Moderna's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its COVID-19 vaccine, which was authorized in the United States in December 2020. Moderna had 44 mRNA development programs as of early 2022, with 25 of these in clinical trials. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
My Portfolios
Create New Portfolio
Portfolio Contest
My Gurus
Personalize
Premium Gurus 
2.46(1.41%) Volume: 3,332,369 11:08PM EDT
Email Alerts
Stock PDF
RSS
Website
Filings
Download
Manual of Stocks™ Web APP
NAS:MRNA has been successfully added to your 
